First patient has been enrolled in the Nuedexta Bulbar Function Study in Providence ALS Center in Portland, Oregon. To see more information about this study, click here.
(Nuedexta is a drug developed at CNS and distributed by Avanir)
top of page
News
Nuedexta gets a positive recommendation from the European Medicines Agency for the treatment of Pseudobulbar effect in patients living in Europe. The article can be found here.
Dr. Smith quoted in recent article in the Alzheimer's Research Forum about using stem cell-based screening method to model ALS.
bottom of page